Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Ready To Launch Fabrazyme And Aldurazyme; User Fee Dates Near

Executive Summary

Genzyme is ready to launch both Fabrazyme and Aldurazyme simultaneously if FDA approvals come through in April, the company says

You may also be interested in...



Genzyme Aldurazyme Patient Registry Will Evaluate AEs, Antibody Formation

BioMarin/Genzyme will develop an Aldurazyme patient registry to evaluate the long-term safety and activity of the product

Genzyme Aldurazyme Patient Registry Will Evaluate AEs, Antibody Formation

BioMarin/Genzyme will develop an Aldurazyme patient registry to evaluate the long-term safety and activity of the product

Fabrazyme Approved; FDA Weighing What Confirmatory Data Will Be Needed

FDA has set a deadline of Jan. 31, 2004 for Genzyme's Fabrazyme confirmatory placebo-controlled trial following its April 24 approval

Related Content

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel